PEspeaks

Oct 18, 2018
In publishing its proposed rule on disclosing drug prices just three weeks before the mid-term Congressional elections, it’s not a big stretch to see the move by the Trump administration as designed for short-term political purposes.
Oct 18, 2018
As pharm execs look to real-world data to aid in translational research and close the gap from traditional clinical trials to real-world efficacy, there are three foundational pillars to build from. Bill Fox reports.
Oct 11, 2018
Pharmaceutical Executive
As this year's installment of our Emerging Pharma Leaders shows, the current roadmap for a career in biopharma requires its own "Waze"-like navigation.
Oct 09, 2018
Pharmaceutical Executive
New life sciences internship program has high-level mission. Michelle Maskaly reports.
Oct 09, 2018
Pharmaceutical Executive
What will come out of Austria’s shakeup of European pharma rules? Reflector reports.
Oct 08, 2018
Leela Barham continues her series of features exploring expedited FDA approvals with a look at the therapy areas and the overlap with orphan drug designations.
Oct 05, 2018
There’s been a lot of talk about speeding up drug approval at FDA. Leela Barham takes a look at the speed of approval for each of FDA's expedited development and review methods.
Oct 03, 2018
Pharmaceutical Executive
A look at the pharmaceutical value chain and how pricing concerns and patient centricity fits in to improving access.
Sep 21, 2018
Pharmaceutical Executive
A look at the Drug Supply Chain Security Act and how it impacts serialization and third-party logistics licensing.
Sep 20, 2018
FDA is joining with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to support innovative new medicines to combat infectious diseases.
native1_300x100
lorem ipsum